|
|
Vaccine Detail
|
Melan-A/Mart-1 |
| Vaccine Information |
- Vaccine Name: Melan-A/Mart-1
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007641
- Type: Peptide
- Status: Research
- Antigen: human leukocyte antigen-A*0201
- Immunization Route: Intramuscular injection (i.m.)
|
| Host Response |
|
Human Response
- Vaccine Immune Response Type: VO_0003057
- Immune Response: Melan-A/Mart-1 specific CD8 T cells were analyzed ex vivo, with positive results in 6 of 14 evaluable patients. Increased percentages of T cells were found in three patients, memory/effector T cell differentiation in 4 patients, and a positive interferon-gamma Elispot assay in 1 patient. Antibody responses to P40 were observed in all patients (Lienard et al., 2009).
|
| References |
Lienard et al., 2009: Lienard D, Avril MF, Le Gal FA, Baumgaertner P, Vermeulen W, Blom A, Geldhof C, Rimoldi D, Pagliusi S, Romero P, Dietrich PY, Corvaia N, Speiser DE. Vaccination of melanoma patients with Melan-A/Mart-1 peptide and Klebsiella outer membrane protein p40 as an adjuvant. Journal of immunotherapy (Hagerstown, Md. : 1997). 2009; 32(8); 875-883. [PubMed: 19752746].
|
|
